■ Research grants & projects
|
1.
|
(Grant No.：21117008)
Budget amount：\28,340,000 (Principal investigator)
|
|
2.
|
Budget amount：\580,000 (Principal investigator)
|
|
3.
|
(Grant No.：23590347)
Budget amount：\1,040,000 (Principal investigator)
|
|
4.
|
(Grant No.：23590309)
Budget amount：\1,300,000 (Principal investigator)
|
|
5.
|
(Grant No.：24501321)
Budget amount：\2,080,000 (Principal investigator)
|
|
6.
|
(Grant No.：24700987)
Budget amount：\1,690,000 (Principal investigator)
|
|
Display 5 items
|
|
Display all(6)
|
|
To the top
|
|
■ Published papers
|
Original article
|
|
1.
|
Maru Yoshiro：
The molecular biology of chronic myeloid leukemia.
Cancer Science
103
(9)
：1601-1610
, 2012.9
|
|
2.
|
FUjita M, Ieguchi K, Davari P, Yamaji S, Taniguchi Y, Sekiguchi K, Takada YK, Takada Y：
Crosstalk between integrin α6β4 and IGF1R through direct α6β4 binding to IGF1 and subsequent α6β4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions.
Journal of Biological Chemistry
287
(15)
：12491-12500
, 2012.4
|
|
To the top
|
|
■ Academic conference presentation
|
1.
|
◎IMAI Yoichi, OHTA Eri, WANG Yanhua, KITAGAWA Yukiko, DING Ye, YAMADA Osamu, MARU Yoshiro, MOTOJI Toshiko：
MLL-HOXA9 and calcineurin are nobel therapeutic targets in multiple myeloma.
54th ASH Annual Meeting and Exposition,
Atlanta, USA,
2012/12
|
|
2.
|
◎Katsuaki Ieguchi, Yoshiro Maru：
Ephrin-A1 expression is up-regulated by S100A8, an endogenous ligand for TLR4, in primary tumor.
International Endotoxin & Innate Immunity Society,
Tokyo, Japan,
2012/10
|
|
3.
|
Hiratsuka Sachie：
Innate immune system mediates focal metastasis.
MRS,
Brisbane, Australia,
2012/07
|
|
4.
|
Maru Yoshiro：
S100A8, amyloid A3, and TLR4 in tumor metastasis.
4th International Muenster Meeting on Danger Signaling in Autoinflammation,
Muenster, Germany,
2012/04
|
|
5.
|
丸義朗, 塚原富士子：
Intramolecular regulatory mechanism of degradation of chronic myeloid leukemia oncoprotein, BCR-ABL.
第８6回日本薬理学会年会,
福岡, 日本,
2013/03
|
|
6.
|
◎今井陽一, 太田瑛里, 王艶華, テインイエ, 山田修, 丸義朗, 泉二登志子：
MLL is a novel target of anti-myeloma therapy and it is degraded by inhibitors of HDAC and HSP90.
第74回日本血液学会学術集会,
京都,
2012/10
|
|
7.
|
◎塚原富士子, 丸義朗：
PP2A promotes immature protein sensor Bag1-mediated BCR-ABL degradation.
第７１回日本癌学会学術総会,
札幌,
2012/10
|
|
8.
|
◎家口勝昭, 丸義朗：
がんの肺転移におけるEph/ephrinの新規昨日である接着分子としての機能解析.
日本癌学会,
札幌、日本,
2012/09
|
|
9.
|
丸 義朗：
SAA3ペプチドによるTLR4シグナルの活性化.
第71回日本癌学会学術総会,
札幌,
2012/09
|
|
10.
|
◎今井陽一, 太田瑛里, 王艶華, テインイエ, 山田修, 丸義朗, 泉二登志子：
多発性骨髄腫における新たな治療標的 MLL は HDAC、HSP90 阻害剤により蛋白質発現量が低下する.
第37回日本骨髄腫学会学術集会,
京都,
2012/07
|
|
11.
|
Maru Yoshiro：
An interface between metastasis and inflammation
International Session Core Symposium 「炎症とがん」.
第71回日本癌学会学術総会,
札幌, 日本,
2012/09
|
|
Display 5 items
|
|
Display all(11)
|
|
To the top
|
|
